Evidence map›Paper›PMID 41807588›Full record

ArticleNPJ precision oncology2026

Copy number alteration fingerprint predicts the clinical response of oxaliplatin-based chemotherapy in metastatic colorectal cancer.

Junyong Weng, Jinyu Wang, Ziyu Tao, Tao Wu, Kaixuan Diao, Jiexuan Wang, Nan Wang, Zilan Ye, Ruoxin Zhang, Jiayu Shen and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Junyong WengDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Jinyu WangSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Ziyu TaoSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Tao WuSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Kaixuan DiaoSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Jiexuan WangDepartment of General Surgery, Tongji hospital, Tongji University School of Medicine, Shanghai, China.
Nan WangSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Zilan YeDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Ruoxin ZhangDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Jiayu ShenSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Xiangyu ZhaoSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
XinXing LiDepartment of General Surgery, Tongji hospital, Tongji University School of Medicine, Shanghai, China. ahtxxxx2015@163.com.
Xinxiang LiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. xinxiangli@fudan.edu.cn.
Xue-Song LiuSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China. liuxs@shanghaitech.edu.cn.

Funding

cross disciplinary Research Fund of Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine JYJC202227National Natural Science Foundation of China 82373149open project fund of the National Health Commission's key laboratory of individualized diagnosis and treatment of nasopharyngeal cancer 2023NPCCK02Shanghai Science and Technology Commission 24J22800700
6 · The paper itself

Abstract

Oxaliplatin-based chemotherapy is a standard treatment for metastatic colorectal cancer (mCRC), yet accurate biomarkers to identify responders remain lacking. In this study, we developed and validated a genomic copy number alteration (CNA)-based biomarker to predict clinical response to oxaliplatin-based chemotherapy. A total of 297 samples were collected, and shallow sequencing was employed to extract CNA features. The resulting model named "CNA fingerprint" is an XGBoost model trained using 7 CNA features. The model was validated across three independent test cohorts from two centers, achieving area under the receiver operating characteristic curve (AUC) of 0.87, 0.87, and 0.85, respectively. The primary predictor was the number of DNA segments with high absolute copy numbers. Our findings suggest that the CNA fingerprint could be used as biomarker for oxaliplatin-based chemotherapy response prediction in mCRC. Further prospective clinical trials are warranted to evaluate CNA fingerprint's performance in clinical applications.

Identifiers

PMID41807588
PMCPMC13103370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.